1. Home
  2. MOBI vs CLLS Comparison

MOBI vs CLLS Comparison

Compare MOBI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mobia Medical Inc. Common Stock

MOBI

Mobia Medical Inc. Common Stock

N/A

Current Price

$10.75

Market Cap

383.0M

Sector

Health Care

ML Signal

N/A

Logo Cellectis S.A.

CLLS

Cellectis S.A.

N/A

Current Price

$1.63

Market Cap

394.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MOBI
CLLS
Founded
N/A
1999
Country
United States
France
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
383.0M
394.4M
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
MOBI
CLLS
Price
$10.75
$1.63
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.33
AVG Volume (30 Days)
154.9K
19.1K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$0.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.01
$2.35
52 Week High
$15.19
$5.48

Technical Indicators

Market Signals
Indicator
MOBI
CLLS
Relative Strength Index (RSI) 39.10 21.37
Support Level N/A N/A
Resistance Level $12.28 $3.47
Average True Range (ATR) 0.84 0.21
MACD -0.12 -0.12
Stochastic Oscillator 6.02 5.41

Price Performance

Historical Comparison
MOBI
CLLS

About MOBI Mobia Medical Inc. Common Stock

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: